전이성 거세 저항성 전립선 암에서 치료 모니터링을 위한 순환 종양 DNA 평가의 부가 가치가 PSA에 추가됨

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. 1Supplementary Figure S10 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer2024
2. 2Supplementary Figure S9 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer2024
3. 3Supplementary Figure S9 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer2024
4. 4Supplementary Figure S8 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer2024
5. 5Supplementary Figure S8 from Circulating Tumor DNA Assessment for Treatment Monitoring Adds Value to PSA in Metastatic Castration-Resistant Prostate Cancer2024